Mecamylamine for Autonomic Dysreflexia Prophylaxis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03914677|
Recruitment Status : Recruiting
First Posted : April 16, 2019
Last Update Posted : October 7, 2019
Wayne State University
Information provided by (Responsible Party):
Edward Nieshoff, MD, Wayne State University
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Recruiting|
|Estimated Primary Completion Date :||March 17, 2020|
|Estimated Study Completion Date :||December 31, 2020|
Braddom RL, Johnson EW. Mecamylamine in control of hyperreflexia. Arch Phys Med Rehabil. 1969 Aug;50(8):448-53 passim.
Braddom RL, Rocco JF. Autonomic dysreflexia. A survey of current treatment. Am J Phys Med Rehabil. 1991 Oct;70(5):234-41.
Eldahan KC, Rabchevsky AG. Autonomic dysreflexia after spinal cord injury: Systemic pathophysiology and methods of management. Auton Neurosci. 2018 Jan;209:59-70. doi: 10.1016/j.autneu.2017.05.002. Epub 2017 May 8. Review.